WuXi PharmaTech (Cayman)
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), WuXi PharmaTech (Cayman) beat expectations for both revenue and earnings per share.
Compared to the prior-year quarter, both revenue and GAAP earnings per share grew significantly.
Gross margin improved, operating margin dropped, and net margin increased.
WuXi PharmaTech (Cayman) logged revenue of $108.5 million. The nine analysts polled by S&P Capital IQ expected to see a top line of $106.9 million on the same basis. GAAP reported sales were 23% higher than the prior-year quarter's $88.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.31. The nine earnings estimates compiled by S&P Capital IQ averaged $0.26 per share on the same basis. GAAP EPS of $0.32 for Q4 were 33% higher than the prior-year quarter's $0.24 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 39.2%, 70 basis points better than the prior-year quarter. Operating margin was 18.6%, 250 basis points worse than the prior-year quarter. Net margin was 21.6%, 210 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $112.2 million. On the bottom line, the average EPS estimate is $0.26.
Next year's average estimate for revenue is $471.0 million. The average EPS estimate is $1.19.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 331 members rating the stock outperform and 22 members rating it underperform. Among 85 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 82 give WuXi PharmaTech (Cayman) a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on WuXi PharmaTech (Cayman) is outperform, with an average price target of $18.27.
Over the decades, small-cap stocks like WuXi PharmaTech (Cayman) have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add WuXi PharmaTech (Cayman) to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.